TOKEN2049
22.9.2022 09:57:04 CEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, announced that it will be showcasing a first-of-its-kind, immersive NFT experience, entitled the OP3N WHALE NFT Exhibition, at its upcoming Singapore edition from 28 to 29 September. The exhibition will be presenting NFT assets with a market value exceeding US$100 million — the first time such a collection owned by a single entity has ever been on display to the public.
The exhibition was developed by OP3N, a launchpad for IP and communities in Web3, and WHALE, the omni-versal membership club with a treasury that includes the world’s largest collection of rare, high-value NFTs spanning gaming, art, and virtual real estate.
Raphael Strauch, Founder of TOKEN2049 said: “Today’s Web3 ecosystem reflects the exciting creativity and innovation being brought by a myriad of industries by way of their growing interest in NFTs — and so much of this is taking place in Asia. We have an exciting programme for our attendees — and this exhibition is just one part.”
Showcasing creatives, brands, and curators from the region that exemplify the global dynamic of East Meets West, the exhibition will make its exclusive debut at Asia’s largest Web3 event and TOKEN2049’s largest-ever conference in its history. An estimated 7,000 visitors are expected to attend.
The exhibition includes artworks by renowned digital artist Pak, famed for spearheading Sotheby’s first-ever NFT sale; leading glitch artist XCOPY; Milanese artist duo Hackatao; and award-winning Asian-American photographer Michael Yamashita.
TOKEN2049 Singapore will also feature a rotating display of generative art masterpieces from New York City’s Museum of Modern Art (MoMA)’s permanent collection artist Brendan Dawes and Instagram photography sensation Ryosuke Kosuge. These works will be displayed at WHALE’s solo booth at the conference.
Renowned NFT collector and WHALE founder WhaleShark, said: “Non Fungible technology has ignited a global digital renaissance of art and culture, and the ability to partner with TOKEN2049 and OP3N to showcase some of the earliest and most renowned pioneers of this sector is truly an honor. The exhibition puts the spotlight on this inevitable revolution of the arts with a focus on a time-tested creative industry rather than the flavor of the month.”
In addition, attendees will be able to see OP3N’s latest NFT drop “A3”, developed by YOON and VERBAL who are behind the iconic Tokyo-based fashion brand AMBUSH®. The iconic phygital “A3” NFT will be uniquely presented in a glass display case on the exhibition floor.
“Art, culture and technology are intersecting in exciting and completely new ways, with many industry firsts taking place around the globe,” said Jaeson Ma, Co-Chief Executive Officer and Founder of OP3N, the world’s preeminent contemporary NFT experience brand. “From digital creators and traditional artists to fashion brands such as AMBUSH who’s been expanding their presence in the NFT space, we’re bringing together an incredible pool of talent to celebrate and honor their work.”
Jaeson will also be speaking on a panel on ‘The Future of IP & Communities in Web3’ on 29 September at 2:45 PM along with VERBAL who will speak more about “A3” in detail.
TOKEN2049 Singapore’s agenda will be featuring a series of discussions touching on the latest developments in the Web3 ecosystem — from the global macro narrative for crypto, the rise of Web3 gaming, the emerging social and creator economy, the future of AI and generative art, present and future Web3 infrastructure, and many more.
As part of Asia Crypto Week, TOKEN2049 attendees can expect to attend a full line-up of side events, conferences, networking events, workshops, and parties taking place throughout the week.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/.
About TOKEN2049
TOKEN2049 is a premier Web3 event, organized annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
About OP3N
Founded in 2021 as a subsidiary of EST Media Holdings, OP3N imagines a world where Communities can come together to create, own, and bring their ideas to the world. OP3N’s mission is to be a Launchpad for Ideas and Communities to create meaningful experiences together. By consolidating the tools needed to mint, share and engage with NFTs and digital tokens into one vertical stack, OP3N leverages its cross-industry expertise from the entertainment, gaming and tech ecosystems, to lay the foundations for a new era of community-driven, inclusive entertainment while bringing everyone together on a journey into Web3. For more information, please visit: https://op3n.world/
About WHALE
WHALE is the omni-versal membership club for the natively digital, focused on immersing WHALE Members in the renaissance of digital art and culture. Powered by the club's native social token, $WHALE, and the club treasury, the WHALE Vault, WHALE delivers physical and metaversal content, information, and experiences for a new generation of digital enthusiasts. Established in 2020 by the pseudonymous WhaleShark, WHALE boasts over 25,000 members worldwide, all focused on the longer-term discussion and immersion of Web 3 and the revolution of true digital asset scarcity, ownership, and management.
About AMBUSH®
AMBUSH® began as an experimental jewelry line – innovative pop art-inspired designs capturing a distinct Tokyo aesthetic. With apparel created as a canvas to complete the story, AMBUSH® evolved into designing unisex collections. The brand made its Paris debut in 2015 with YOON & VERBAL being listed as two of Business of Fashion’s Top 500 people influencing the global fashion industry for 5 consecutive years from 2015, and HYPEBEAST 100 list for 8 consecutive years. In 2017 AMBUSH® was selected as one of the top 8 finalists for the LVMH PRIZE. In 2018, AMBUSH® debuted at Amazon Fashion Week Tokyo. In the same year, Kim Jones named YOON as jewelry designer for Dior Men. In 2022, AMBUSH® presented the brand’s first runway at Milan Fashion Week and launched its proprietary metaverse SILVER FCTRY. Its first POW!® NFT collection sold out in minutes, ranking it among the top 10 projects on Opensea, and the second most transacted NFT from Japan at the time of its debut.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005455/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom